Skip to main content
Defiance International

Published study records

Study records for VIP

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

4,874 study records.

71 evidence-verified · 3,324 citation-verified · 1,479 identifier-confirmed · 0 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 1,407
  • In vivo/preclinical: 1,745
  • Review/meta-analysis: 186
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2017

Paradoxical response reversal of top-down modulation in cortical circuits with three interneuron types.

eLife · 2017

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not reported in the declared source.

Participants or experimental system

Not reported in the declared source.

Study scale

Not reported in the declared source.

Intervention or exposure

Not reported in the declared source.

Comparator

Not reported in the declared source.

Outcomes examined

Not reported in the declared source.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2016

Characterization of Na+-K+-2Cl- Cotransporter Activity in Rabbit Lacrimal Gland Duct Cells.

Investigative ophthalmology & visual science · 2016

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

Interlobular ducts were isolated from fresh rabbit LG tissue.

Study scale

Not reported in the declared source.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

Behavioral-state modulation of inhibition is context-dependent and cell type specific in mouse visual cortex.

eLife · 2016

Study scale: At each focal plane (n = 100 fields of view), 8–12 trials (60 s duration) were acquired in total darkness and 12–20 trials acquired during visual stimulation, with dark and visual stimulation trials randomly interleaved.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In this study, we tested this hypothesis by directly comparing the locomotion responses of excitatory and inhibitory neurons in darkness and during visual stimulation.

Study design

Individual periods of locomotion separated by stationary periods (epochs) were divided into odd and even epochs and mean LMIs were calculated for each context (darkness and visual stimulation).

Participants or experimental system

We used two-photon calcium imaging to monitor the activity of excitatory neurons as well as of three non-overlapping populations of inhibitory neurons (VIP, SST and parvalbumin [PV] neurons) in layer 2/3 and layer 4 of V1 in awake behaving mice.

Study scale

At each focal plane (n = 100 fields of view), 8–12 trials (60 s duration) were acquired in total darkness and 12–20 trials acquired during visual stimulation, with dark and visual stimulation trials randomly interleaved.

Intervention or exposure

Adeno-associated viruses (AAVs) were injected using a pipette with 20 μm tip diameter (Nanoject, Drummond Scientific, PA) at a speed of 10 nl min−1 at three different depths (around 250, 400, and 600 μm deep; 50 nl per site).

Comparator

Not reported in the declared source.

Outcomes examined

We compared the modulation of neuronal activity by locomotion in the mouse primary visual cortex (V1), between two different sensory contexts: darkness and visual stimulation.

Limitations and uncertainty

Consequently, potential confounding factors in the present study would be (1) different intracellular calcium dynamics in different types of inhibitory neurons as well as (2) a higher increase of cytosolic free calcium concentration for the same number of spikes during locomotion compared to stationary periods.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Journal of neuroinflammation · 2016

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Here, we investigated the involvement of VPAC1 in the development of EAE using a VPAC1-deficient mouse model.

Study design

Not reported in the declared source.

Participants or experimental system

EAE was induced in wild-type (WT) and VPAC1 knockout (KO) mice using myelin oligodendrocyte glycoprotein 35–55 (MOG35–55), and clinical scores were assessed continuously over 30 days.

Study scale

Not reported in the declared source.

Intervention or exposure

Two hundred nanograms of Pertussis toxin (List Biological Laboratories) was administered intraperitoneally (i.p.) to the mice on the immunization day as well as 2 days later.

Comparator

The percent donor composition was determined by measuring the percentage of CD45.2 (donor) vs. CD45.1 (recipient) in whole blood cells in the recipient mice before EAE induction.

Outcomes examined

The contribution of VPAC1 expression in the immune system to the development of EAE was evaluated by means of adoptive transfer and bone marrow chimera experiments.

Limitations and uncertainty

In our studies with a VPAC1 antagonist treatment, a long-term administration before EAE induction led to a lack of EAE similar to that found in VPAC1 KO mice.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2016

VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.

Scientific reports · 2016

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In this sense, we investigated whether the in vivo treatment with VIP contributes to an immunosuppressant local microenvironment associated with an improved pregnancy outcome in the CBA/J × DBA/2 resorption prone model.

Study design

IL-10 production was quantified in macrophages of pregnant CBA/J females after in vivo treatment with PBS or VIP before and after efferocytosis.

Participants or experimental system

Mice were bred and maintained on a 12:12 h light–dark schedule in the Central Animal Care facility at the School of Exact and Natural Sciences, University of Buenos Aires (FCEyN-UBA).

Study scale

Not reported in the declared source.

Intervention or exposure

CBA/J × DBA/2 pregnant mice were treated in vivo with VIP or PBS, as described, and at day 8.5 the implantation sites were obtained and Foxp3/RORγt expression ratio was evaluated by RT-PCR.

Comparator

As shown in Fig. 5A, the control mice that were not treated with VIP had higher levels of IL-12 while the CBA/J group treated with VIP did not modulate IL-12 levels (Fig. 5A).

Outcomes examined

First of all, we studied the expression of VIP and its high affinity receptors (VPAC1 and VPAC2) in viable implantation sites.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2015

Electrophysiological Studies into the Safety of the Anti-diarrheal Drug Clotrimazole during Oral Rehydration Therapy.

PLoS neglected tropical diseases · 2015

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Jejunal tissue preparations were apically and basolaterally treated with 5, 30, and 150 μM clotrimazole (CLT) or vehicle control for 20 minutes in Ussing chambers and subsequently challenged with the cAMP-dependent secretagogue VIP (7.5 nm) or the Ca2+-dependent secretagogue carbachol (20 μM).

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2015

Periosteum Metabolism and Nerve Fiber Positioning Depend on Interactions between Osteoblasts and Peripheral Innervation in Rat Mandible.

PloS one · 2015

Study scale: Forty 8 weeks-old rats were distributed at random in two lots.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

To this goal, VIP content and/or activity were modulated in vivo and the impact on osteoblast activity and expression of NGF and sema3a was determined.

Participants or experimental system

Eight weeks-old male Wistar rats (Iffa Credo, L’Arbresle, France), weighing 250 ± 20 g, fed a standard rodent diet (M25 Extralabo; UAR, Villemoisson, France) were used.

Study scale

Forty 8 weeks-old rats were distributed at random in two lots.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Twenty rats were sham-treated with daily saline ip injections and used as controls.

Outcomes examined

In the non-osteogenic compartment, we quantified (a) the number of ßNGF+ mast cells (N/mm of adjacent bone surface).

Limitations and uncertainty

While these data show that the cholinergic innervation significantly impacts osteoblastic cell behavior, how these cells act on the fibers innervating the periosteum remains unknown.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2013

A Gq-Ca2+ axis controls circuit-level encoding of circadian time in the suprachiasmatic nucleus.

Neuron · 2013

Study scale: One week after transduction, strong signal was evident in neurons across the SCN and overall fluorescence was highly circadian, with estimated [Ca2+]i ranging between 113 ± 7.5nM (nadir) and 191 ± 25nM (zenith, mean ± SEM n = 3, see Experimental Procedures; Figure 4A; Movie S2).

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Having characterized this program, and shown its dependence upon neuropeptidergic G-coupled signaling, we then sought to examine causal relationships within it.

Study design

Not reported in the declared source.

Participants or experimental system

VIP-IRESCre (Viptm1(cre)Zjh/J) and R26 floxed STOP EYFP (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA).

Study scale

One week after transduction, strong signal was evident in neurons across the SCN and overall fluorescence was highly circadian, with estimated [Ca2+]i ranging between 113 ± 7.5nM (nadir) and 191 ± 25nM (zenith, mean ± SEM n = 3, see Experimental Procedures; Figure 4A; Movie S2).

Intervention or exposure

Not reported in the declared source.

Comparator

Vehicle treated SCN received ddH2O as vehicle treatment.

Outcomes examined

To test this, the spatiotemporal dynamics of Per2:luc and Cry1-luc expression were analyzed.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2013

Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

PloS one · 2013

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In the present study, we aimed to evaluate the vasodilatory potential of the synthetic, stable VIP analog RO 25-1553 in the pulmonary circulation.

Study design

In a second set of experiments, we tested whether RO 25-1553 exerts a similar vasodilatory effect in the pulmonary vasculature when a) administered by inhalation and b) in an in vivo setting rather than an isolated organ preparation.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not reported in the declared source.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2012

Plasma hormones facilitated the hypermotility of the colon in a chronic stress rat model.

PloS one · 2012

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

Male Wistar rats were submitted daily to 1-h of water avoidance stress (WAS) or sham WAS (SWAS) for 10 consecutive days.

Study scale

Not reported in the declared source.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Fecal pellets found in the tank were counted at the end of each 1-h WAS or sham WAS session.

Outcomes examined

The weight of the rats was measured every day before exposure to WAS or sham WAS to evaluate weight change from baseline.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2012

Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons.

BMC gastroenterology · 2012

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Aims of the present study were to investigate possible neuroprotective effects of GLP1, GLP2 and VIP on myenteric neurons from adult rat small intestine.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

GLP1, GLP2 and VIP were added to cultured myenteric neurons from rat small intestine or to co-cultures of myenteric neurons and rat peritoneal mast cells.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not reported in the declared source.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2009

Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands.

Arthritis research & therapy · 2009

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The aim of the present study was to analyse apoptotic events involving TNF-α/TNF-αR in isolated acini from NOD mice submandibular glands and to explore the ability of VIP to modulate these effects.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked